TBKBP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20
SCHEMBL22024567	0.81	2/20
SCHEMBL4699140	0.80	2/20
SCHEMBL4922941	0.80	2/20
SCHEMBL4916509	0.78	2/20
SCHEMBL21943725	0.78	2/20
SCHEMBL22024563	0.78	2/20
SCHEMBL4700123	0.77	2/20
SCHEMBL21943339	0.76	2/20
SCHEMBL4698636	0.76	2/20

Clinical trials — most relevant to TBKBP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients	PHASE2	ACTIVE_NOT_RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]	PHASE2	UNKNOWN
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	PHASE1	COMPLETED
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle	nan	COMPLETED
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients	nan	COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma	nan	COMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
TL1A Expression in Psoriatic Skin	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TBKBP1 binder may also engage these)

Protein	Name	Similarity
A2A9T0	—	1.000	A2A9T0 →
Q6DG50	—	1.000	Q6DG50 →
A5PKL7	—	0.996	A5PKL7 →
A0A8I3QA39	—	0.994	A0A8I3QA39 →
F1MRK3	—	0.994	F1MRK3 →
Q3LUD4	—	0.993	Q3LUD4 →
Q8K1Q4	—	0.993	Q8K1Q4 →
Q9Y2J4	—	0.993	Q9Y2J4 →
A2AHG0	—	0.992	A2AHG0 →
O14529	—	0.992	O14529 →
A2AEV7	—	0.992	A2AEV7 →
Q5JTD0	—	0.992	Q5JTD0 →
O60299	—	0.991	O60299 →
Q9JIR0	—	0.991	Q9JIR0 →
G3V735	—	0.991	G3V735 →
Q569K6	—	0.990	Q569K6 →
Q8K3I4	—	0.990	Q8K3I4 →
Q8IYY4	—	0.990	Q8IYY4 →
Q5RCR6	—	0.989	Q5RCR6 →
Q9EP53	—	0.989	Q9EP53 →
Q9C0H5	—	0.988	Q9C0H5 →
Q499E4	—	0.988	Q499E4 →
Q9C0H9	—	0.988	Q9C0H9 →
Q63ZY3	—	0.988	Q63ZY3 →
Q91YU6	—	0.988	Q91YU6 →
Q148V8	—	0.988	Q148V8 →
Q9BRK4	—	0.988	Q9BRK4 →
A4IFI1	—	0.987	A4IFI1 →
Q8BL43	—	0.987	Q8BL43 →
E1U8D0	—	0.987	E1U8D0 →